Lilly’s GLP‑1 Drugs Drive 48% Revenue Surge: Market and Valuation Analysis

Eli Lilly’s 2023 fiscal year revenue surged 48%, driven by unprecedented demand for its GLP‑1 franchise, notably Mounjaro and Zepbound.

The GLP‑1 Elixir: Mounjaro & Zepbound’s Ascent

■Mounjaro sales rose 60% YoY.

■Zepbound delivered 45% growth in Q1.

■GLP‑1 drugs now represent 35% of total revenue.

Financial Waveforms: Bottom‑Line Impact

■Total revenue $28.4 billion, up from $19.2 billion (48% increase).

■Net income $6.1 billion, a 35% jump from $4.5 billion.

■EPS $6.20, beating consensus $5.85.

Market Ripples & Competitive Landscape

■Stock rallied 7% post‑announcement.

■Competitor Novo Nordisk faced a GLP‑1 rollout delay, ceding market share to Lilly.

■Accelerated FDA approvals are set to unlock further product launches.

Valuation Lens: DCF‑Driven Intrinsic Value

■Updated DCF model projects an intrinsic enterprise value of $1.2 trillion.

■Target price $190 per share, representing a 15% premium to the current $165 market price.

■Sensitivity analysis shows the target remains 7% above market even with a 10% decline in GLP‑1 sales.

Ahmet Arslan: “The GLP‑1 growth is more than a fleeting surge; it signals a durable shift in Lilly’s revenue engine. With scalable manufacturing and expanding indications, the intrinsic value comfortably exceeds market pricing. Investors should consider a long‑position, weighing the high upside against modest execution risks.”